148 related articles for article (PubMed ID: 17638914)
1. The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.
Wallace A; LaRosa DF; Kapoor V; Sun J; Cheng G; Jassar A; Blouin A; Ching LM; Albelda SM
Cancer Res; 2007 Jul; 67(14):7011-9. PubMed ID: 17638914
[TBL] [Abstract][Full Text] [Related]
2. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
3. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
4. 5,6-Dimethylxanthenone-4-acetic acid treatment of a non-immunogenic tumour does not synergize with active or passive CD8+ T-cell immunotherapy.
Matthews KE; Hermans IF; Roberts JM; Ching LM; Ronchese F
Immunol Cell Biol; 2006 Aug; 84(4):383-9. PubMed ID: 16834573
[TBL] [Abstract][Full Text] [Related]
5. Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents.
Zeng Q; Peng S; Monie A; Yang M; Pang X; Hung CF; Wu TC
Hum Gene Ther; 2011 Jul; 22(7):809-19. PubMed ID: 21128743
[TBL] [Abstract][Full Text] [Related]
6. Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404).
Wang LC; Thomsen L; Sutherland R; Reddy CB; Tijono SM; Chen CJ; Angel CE; Dunbar PR; Ching LM
Neoplasia; 2009 Aug; 11(8):793-803. PubMed ID: 19649209
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
[TBL] [Abstract][Full Text] [Related]
8. p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
Wu Q; Quan H; Xu Y; Li Y; Hu Y; Lou L
J Pharmacol Exp Ther; 2012 Jun; 341(3):709-17. PubMed ID: 22414857
[TBL] [Abstract][Full Text] [Related]
9. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
10. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cao Z; Baguley BC; Ching LM
Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
[TBL] [Abstract][Full Text] [Related]
11. Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines.
Peng S; Monie A; Pang X; Hung CF; Wu TC
J Biomed Sci; 2011 Mar; 18(1):21. PubMed ID: 21385449
[TBL] [Abstract][Full Text] [Related]
12. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
[TBL] [Abstract][Full Text] [Related]
13. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
14. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
15. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Chung F; Liu J; Ching LM; Baguley BC
Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
[TBL] [Abstract][Full Text] [Related]
16. The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis.
Roberts ZJ; Goutagny N; Perera PY; Kato H; Kumar H; Kawai T; Akira S; Savan R; van Echo D; Fitzgerald KA; Young HA; Ching LM; Vogel SN
J Exp Med; 2007 Jul; 204(7):1559-69. PubMed ID: 17562815
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model.
Yoshida S; Shime H; Takeda Y; Nam JM; Takashima K; Matsumoto M; Shirato H; Kasahara M; Seya T
Cancer Sci; 2018 Apr; 109(4):956-965. PubMed ID: 29465830
[TBL] [Abstract][Full Text] [Related]
18. Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1.
Liu H; Innamarato PP; Kodumudi K; Weber A; Nemoto S; Robinson JL; Crago G; McCardle T; Royster E; Sarnaik AA; Pilon-Thomas S
Oncotarget; 2016 Jun; 7(25):37893-37905. PubMed ID: 27177220
[TBL] [Abstract][Full Text] [Related]
19. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents.
Kuhn S; Hyde EJ; Yang J; Rich FJ; Harper JL; Kirman JR; Ronchese F
J Immunol; 2013 Aug; 191(4):1984-92. PubMed ID: 23858033
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]